主要目的：评价 MH048 在复发/难治性 B-NHL 患者中的安全性及耐受性，确定 MH048 的最大耐受剂量（MTD）和推荐Ⅱ期临床剂量（RP2D）次要目的：研究 MH048 及其活性代谢产物 M3 在复发/难治性 B-NHL 患者中的药代动力学特性。获得 MH048 在复发/难治性慢 B-NHL 患者中的抗肿瘤活性的初步数据。

开始日期2021-12-07

申办/合作机构

明慧医药（上海）有限公司

CTR20202457 / Recruiting临床1期

MH048 用于复发/难治性 B 细胞恶性肿瘤患者的安全性、药代动力学以及抗肿瘤药效的多中心、开放标签、剂量递增及队列扩展 Ⅰ/Ⅱ 期临床研究

主要目的：评价 MH048 在复发/难治性 B-NHL 患者中的安全性及耐受性确定 MH048 的最大耐受剂量（MTD），并基于方案定义的剂量限制性毒性次要目的：研究 MH048 及其活性代谢产物 M3 在复发/难治性 B-NHL 患者中的药代动力学特性。获得 MH048 在复发/难治性慢 B-NHL 患者中的抗肿瘤活性的初步数据。

开始日期2021-01-07

申办/合作机构

明慧医药（上海）有限公司

NCT04689308 / Unknown status临床1期

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of MH048 in Subjects With Selected Relapsed/Refractory B-cell Malignancies

This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.

开始日期2021-01-07

申办/合作机构

明慧医药（杭州）有限公司初创企业

100 项与 MH-048 相关的临床结果

登录后查看更多信息

100 项与 MH-048 相关的转化医学

登录后查看更多信息

100 项与 MH-048 相关的专利（医药）

登录后查看更多信息

项与 MH-048 相关的文献（医药）

2005-01-01·Medicina (Kaunas, Lithuania)4区 · 医学

New xanthone derivatives as potent anti-inflammatory agents.

4区 · 医学

ArticleOA

作者: Librowski, Tadeusz ; Czarnecki, Ryszard ; Czekaj, Teresa ; Marona, Henryk

MATERIAL AND METHODS:

Acute inflammation was induced by subplantar injection of 0.1 ml of 1% carrageenan solution to the right rat paw, 1 hour after oral administration of the investigated compound. The development of paw edema was measured plethysmographically. Pain threshold in the hind paw of rat affected by inflammation was measured using an analgesimeter 4 hours after oral administration of the compounds. Mean pain thresholds were calculated for treated and control groups and the percent change from control was determined. Thus we observed irritation of gastric mucosa after use of compounds, which showed significant anti-inflammatory activity. The mucosa of the glandular part of the stomach was inspected using a binocular microscope.

RESULTS:

The preliminary investigation of the anti-inflammatory activity of the novel xanthone derivatives showed uneven anti-inflammatory and analgesic activity. The highest anti-inflammatory and analgesic activity was provided by compound MH-44. The compounds MH-41, MH-43 and MH-48 potentiated the carrageenan edema and lowered the threshold pain in comparison with control. Side effects of the active compound were examined on gastric mucosa and stomach and none of the active compounds showed significant side effects compared with nonsteroidal anti-inflammatory drugs.

CONCLUSIONS:

None of the active compounds showed significant side effects compared with nonsteroidal anti-inflammatory drugs.

100 项与 MH-048 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
B细胞恶性肿瘤	临床2期	中国	明慧医药（上海）有限公司	2021-12-07
肿瘤	临床1期	中国	明慧医药（杭州）有限公司初创企业	2021-01-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04689308 (ASCO2022) 人工标引	临床1期	慢性淋巴细胞白血病	12	MH048	鑰網壓構積鑰襯遞齋膚(膚積蓋襯鏇廠築壓獵範) = Drug-related grade 3 TEAEs included platelet count decrease, neutrophil count decrease, lipase increase, and hypertension (one patient for each). 廠鬱糧築鑰選鬱衊繭鑰 (壓憲鏇簾鑰顧壓鬱壓遞 ) 更多	积极	2022-06-02